Form 4: Sarepta Therapeutics EVP Ryan Brown Reports Stock Sales to Cover Tax Obligations
SEC Form 4 Filing
EVP and General Counsel of Sarepta Therapeutics, Ryan Edward Brown, reports the sale of company stock to cover tax withholding obligations related to vesting restricted stock units.
Summary
- Ryan Edward Brown, EVP and General Counsel of Sarepta Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
- On March 7, 2024, 506 shares of common stock were sold at $120.49 per share to cover tax obligations related to vesting restricted stock units granted on March 6, 2023.
- On March 8, 2024, 899 shares of common stock were sold at $123.14 per share to cover tax obligations related to vesting restricted stock units granted on March 7, 2022.
- Following these transactions, Brown directly owns 28,688 shares of Sarepta Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to stock transactions by a company executive to cover tax obligations. It doesn't inherently indicate positive or negative sentiment about the company's performance.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Key Dates
| Date | Description |
|---|---|
| 03/07/2022 | Date of restricted stock units grant related to the March 8, 2024 stock sale. |
| 03/06/2023 | Date of restricted stock units grant related to the March 7, 2024 stock sale. |
| 03/07/2024 | Date of first stock sale to cover tax obligations (506 shares at $120.49). |
| 03/08/2024 | Date of second stock sale to cover tax obligations (899 shares at $123.14). |
| 03/11/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.